Humana Shifts Focus to Margin Recovery, Targets Insurance Margins Above 3% by 2028

Earnings
โดย Zacks Investment Research·Read original
Summary · why it matters

Humana is shifting its focus from membership growth to earnings improvement, aiming to restore insurance margins to above 3% by 2028 after two years of elevated medical costs. First-quarter 2026 adjusted earnings reached $10.31 per share, beating the Zacks Consensus Estimate by 3.5%, while the insurance benefit ratio dropped to 89.4%, below management's 90% ceiling. The company remains on track for approximately 25% growth in individual Medicare Advantage membership this year and is pursuing disciplined pricing, exiting less profitable markets, and streamlining operations, including selling its remaining stake in Gentiva. CenterWell revenues increased 19.7% year over year to $6.1 billion in the first quarter, highlighting Humana's competitive advantage in integrating technology with patient care. Shares have gained 40.2% year to date, outperforming the broader industry's 22.2% increase, and the stock carries a Zacks Rank of 3, or Hold.

Impact on stocks 3

Aging Population▲ · 2 stocks
Humana Inc
HUM
▲ PositiveCapitalrelevance

Humana reported Q1 2026 adjusted earnings of $10.31 per share, beating estimates, and targets insurance margins above 3% by 2028.

Health Care▲ · 1 stocks

Theme Impact 2

Off-coverage companies 1

GentivaPrivate▼ Negative
Capitalrelevance

Humana is selling its remaining stake in Gentiva, indicating divestiture.

Related news

CVS Omnicare Wins Court Approval for Chapter 11 Liquidation

A Texas bankruptcy judge has approved a wind-down Chapter 11 plan for CVS Omnicare, the long-term care pharmacy subsidiary of CVS Health, after the company sold its business operations for $250 million and reached a $440 million settlement with the Justice Department over an improper billing case. Judge Stacey G. C. Jernigan of the U.S. Bankruptcy Court for the Northern District of Texas approved the plan, noting it received overwhelming acceptance from general unsecured creditors. Omnicare, which CVS has owned since 2015 and which serves nursing homes, assisted living centers, and long-term care and rehab facilities, filed for bankruptcy in September 2025, months after a $949 million judgment for fraudulently dispensing drugs without valid prescriptions to elderly and disabled patients. The government resolved that judgment through the $440 million settlement, which requires CVS to pay $130 million upfront and cover the remaining $310 million if Omnicare fails to pay by March 2028. The purchaser, GenieRx Holdings, is a joint partnership between Milrose Capital LLC and Integro Asset Management LLC, and Omnicare attorney Martha Wyrick of Haynes and Boone LLP said the sale is expected to close next month.
AMZNCVS
Aging Population
TheStreet·18hRead more →
▲

Healthpeak Raises 2026 Guidance on Portfolio Sales and Janus Living Growth

Healthpeak Properties raised its full-year 2026 guidance for the second time this year, now expecting diluted earnings per share of $0.48 to $0.52, up from $0.46 to $0.50, and diluted FFO as Adjusted of $1.73 to $1.77, two cents higher at the midpoint than its prior outlook. The healthcare real estate owner signed 1.6 million square feet of new and renewal leases in the quarter, lifting outpatient medical occupancy 20 basis points to 90.7% and lab occupancy 80 basis points to 78.5%. Growth was led by Janus Living, the senior housing operator Healthpeak controls with a 73.6% stake, where revenue jumped 45% year over year to $216 million and Adjusted EBITDA rose 34% to $79 million, with same-store margins expanding 250 basis points. Healthpeak funded buybacks and debt paydown largely by selling stakes in existing buildings, including July's recapitalization that sold a 49% stake in an 86-property outpatient medical portfolio to Brookfield for roughly $1.025 billion at a 5.9% cap rate, part of $1.4 billion of proceeds generated in the quarter and through August 3. Lab same-store net operating income fell 3.2%, the only one of Healthpeak's three core businesses to shrink, holding total company-wide same-store NOI growth to 1.8%.
DOC ▲JAN ▲BAM
Aging Population ▲
Insider Monkey·1dRead more →

Aevis Victoria H1 2026 NAV Rises 7% as Healthcare Margins Improve

Aevis Victoria reported a net asset value of CHF26.75 per share for H1 2026, up nearly 7% year-over-year and 2.3% versus the prior year-end level, while the discount to NAV remained above 50%, which management described as unprecedented in the group's history. Within the healthcare segment, Swiss Medical Network's EBITDA margin improved from 18.6% to 21.6%, and ambulatory services turned EBITDA-positive for the first time, with its margin rising from 7.1% to 11.8%. The company set a healthcare EBITDA margin target of 23% with organic growth of 2% to 3% per year, noting mature hospitals representing over 50% of the portfolio can reach more than 25% to 26% EBITDA margin while ramp-up hospitals sit at 10% to 20%. Interest expenses declined 43% year-over-year, consolidated net debt stood at CHF846 million with the bulk under Swiss Hotel Property, Swiss Medical Network's net debt-to-EBITDA was approximately 2.2x to 2.3x, and loan-to-value for the real estate business fell to 45%. Chief Financial Officer Michel Keusch cited three catalysts to narrow the discount to NAV: a next phase of value crystallization through selling stakes to strategic shareholders, including the officially announced search for strategic investors in Swiss Medical Network; enhanced investor relations with more roadshows, a Capital Markets Day and greater financial transparency; and a near-quintupling of average daily liquidity over the past two years.
AEVS.SW ▲
Aging Population
GuruFocus·1dRead more →
© 2026 MarketDXNews